This year long study carried out by Medical Decision Modeling in Indianapolis set out to measure the cost-effectiveness of the olanzapine long-acting injection with other antipsychotic long-acting injections and oral olanzapine in treating patients with schizophrenia who had trouble adhering to oral drug treatment. The study used a micro-simulation economic decision model to replicate usual care. [read the full story…]
The manufacturer of agomelatine (Servier) has informed NICE that it would not be making an evidence submission for the appraisal of agomelatine for the treatment of major depressive episodes. Servier drew attention to the fact that NICE guidelines for England and Wales recommend generic selective serotonin reuptake inhibitors (SSRIs) as first-line treatment followed by a [read the full story…]
Researchers from Manchester University have conducted one of the largest randomised controlled trials ever undertaken to investigate self-harm in adolescents. The trial published in the BMJ examined the effectiveness and cost-effectiveness of group therapy for self harm in young people by randomising 366 patients to: Manual based developmental group therapy programme specifically designed for adolescents [read the full story…]
Teenagers with depression sometimes do not respond to treatment with SSRI antidepressants and this inevitably leads to a higher cost of treatment. This randomised controlled trial (conducted by researchers from Kaiser Permanente Northwest in Portland, Oregon) set out to evaluate the incremental cost-effectiveness over 24 weeks of combined cognitive behavior therapy plus switch to a different antidepressant [read the full story…]
Previous studies have reported that the use of applied behaviour analysis by a specialist team in addition to standard treatment for adults with learning disabilities and challenging behaviour was both clinically effective and cost-effective after 6 months. This study reported a 2-year follow-up of the same trial cohort. The study found that participants who were [read the full story…]
